A Phase 3 interventional study of obicetrapib 10 mg + ezetimibe 10 mg FDC daily and Obicetrapib 10 mg in Lipidemia, Type 2 Diabetes (T2DM) and Metabolic Syndrome (MetS), sponsored by NewAmsterdam Pharma. Active, not recruiting at 55 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by NewAmsterdam Pharma · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 338 studies in Hyperlipidemias with a site in United States — 30 open to participants now, 45 under way, 10 of them phase 3. Hyperlipidemias · United States.
Among the 338 studies in Hyperlipidemias with a site in United States, this one is the 95th largest by planned enrollment of the 306 interventional ones that give a count, is one of 18 that started in 2025, is one of 73 in phase 3, reaches primary completion later than 31 of the 44 other live ones, and was the 330th registered.
862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.
Browse Hyperlipidemias studies →30 of the 338 studies in Hyperlipidemias with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Men only
Colorado Prevention Center · Sites in United States
Ages 18+
University of Alabama at Birmingham · Sites in United States
Ages 30–79 · Women only
Cambridge Health Alliance · Sites in United States
Ages 18–60
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
338 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 54 · Phase 3 77 · Phase 4 23
First in 1976; this study’s year is marked. 18 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 88 across 735 interventional studies indexed under Hyperlipidemias.
Median enrollment 120 across the 306 interventional studies, 104 across the 29 observational. Of the 271 that completed or were terminated, 109 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
119 of 338 have an industry lead sponsor. The 10 most frequent:
NewAmsterdam Pharma is the lead sponsor of 20 studies on the registry; 3 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 8 (62%) have results posted.
NewAmsterdam Pharma has 2 studies filed under Hyperlipidemias — fewer than ten, so there is no comparison to draw.
20 of the studies in Hyperlipidemias with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT02262832Phase 3National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy | 2027-07-31 |
| NCT06305559Phase 3NewAmsterdam PharmaA CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | 2027-11 |
| NCT06062394University of PennsylvaniaPenn Medicine Healthy Heart | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 338 studies in Hyperlipidemias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will be a placebo-controlled, double-blind, randomized, Phase 3 study to evaluate the efficacy, safety, and tolerability of obicetrapib 10 mg, both as a fixed-dose combination (FDC) with ezetimibe 10 mg and as monotherapy, on top of guideline-recommended lipid-lowering therapy in patients with metabolic syndrome and/or Type 2 Diabetes Mellitus.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily
obicetrapib 10 mg daily
Drug: Obicetrapib 10 mg
Placebo on top of guideline-recommended lipid-lowering therapy
Other: Placebo
Open-Label Extension (OLE) with the FDC of Obicetrapib 10 mg and Ezetimibe 10 mg
Drug: obicetrapib 10 mg + ezetimibe 10 mg FDC daily
Drug page: TA-8995
FDC
monotherapy
placebo on top of guideline-recommended lipid modifying therapy
The percent change from Baseline to Day 84 in LDL-C compared with placebo for the following treatment groups: - obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group; and - obicetrapib 10 mg monotherapy treatment group
Time frame: 84 days
Percent change from Baseline to Day 84 in non-HDL-C for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group
Time frame: Day 84
Percent change from Baseline to Day 84 in HDL-C for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group
Time frame: 84 days
Percent change from Baseline to Day 84 in ApoB for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group
Time frame: 84 days
Percent change from Baseline to Day 84 in ApoA1 for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group
Time frame: 84 days
Percent change from Baseline to Day 84 in non-HDL-C for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group;
Time frame: 84 days
Percent change from Baseline to Day 84 in HDL-C for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group
Time frame: Day 84
Percent change from Baseline to Day 84 in ApoB for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group
Time frame: Day 84
Percent change from Baseline to Day 84 in ApoA1 for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group
Time frame: Day 84
Percent change from Baseline to Day 84 in lipoprotein (a) (Lp[a]) for the obicetrapib 10 mg + ezetimibe 10 mg FDC treatment group compared with the placebo group
Time frame: Day 84
Percent change from Baseline to Day 84 in Lp(a) for the obicetrapib 10 mg monotherapy treatment group compared with the placebo group
Time frame: Day 84
Percent change from Baseline over time in LDL-C
The percent change from Baseline at every visit for LDL-C
Time frame: 40 weeks
Proportion of participants that achieve LDL-C <100 mg/dL (<2.6 mmol/L), LDL-C <70 mg/dL (<1.8 mmol/L), and LDL-C <55 mg/dL (<1.4 mmol/L)
The percent change from Baseline at every visit in the proportion of participants that achieve LDL-C \<100 mg/dL (\<2.6 mmol/L), LDL-C \<70 mg/dL (\<1.8 mmol/L), and LDL-C \<55 mg/dL (\<1.4 mmol/L)
Time frame: 40 weeks
Percent change from Baseline over time in non-HDL-C
The percent change from Baseline at every visit for non-HDL-C
Time frame: 40 weeks
Percent change from Baseline over time in ApoB
The percent change from Baseline at every visit in ApoB
Time frame: 40 weeks
Percent change from Baseline over time in total cholesterol
The percent change from Baseline at every visit for total cholesterol
Time frame: 40 weeks
Percent change from Baseline over time in triglycerides
The percent change from baseline at every visit for triglycerides
Time frame: 40 weeks
Percent change from Baseline over time in HDL-C
the percent change from Baseline at every visit for HDL-C
Time frame: 40 weeks
Percent change from Baseline over time in Lp(a)
the percent change from Baseline at every visit for Lp(a)
Time frame: 40 weeks
Plan to share: Yes
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for Mar 2028, 27 months after the start.
Of 51 industry-sponsored phase 3 interventional studies under Hyperlipidemias, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's planned 27 months is above that.
Counting every sponsor, half of 57 studies reached it within 18 months; a quarter within 11 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TA-8995
NewAmsterdam Pharma